Menu Search
Equities

Brooks Laboratories Ltd

BROOKS:NSI

Brooks Laboratories Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)147.47
  • Today's Change-3.01 / -2.00%
  • Shares traded25.94k
  • 1 Year change+48.36%
  • Beta2.1454
Data delayed at least 15 minutes, as of Sep 20 2024 10:44 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in INRIncome statement in INRView more

Year on year Brooks Laboratories Ltd grew revenues 25.76% from 632.05m to 794.86m while net income improved from a loss of 209.00m to a smaller loss of 195.92m.
Gross margin29.09%
Net profit margin-21.46%
Operating margin2.13%
Return on assets--
Return on equity--
Return on investment--
More ▼

Cash flow in INRView more

In 2024, Brooks Laboratories Ltd increased its cash reserves by 440.95%, or 1.02m. Cash Flow from Financing totalled 96.01m or 12.08% of revenues. In addition the company used 96.81m for operations while cash from investing totalled 1.82m.
Cash flow per share-6.16
Price/Cash flow per share--
Book value per share--
Tangible book value per share--
More ▼

Balance sheet in INRView more

Brooks Laboratories Ltd uses little or no debt in its capital structure.
Current ratio--
Quick ratio--
Total debt/total equity--
Total debt/total capital--
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.